Impact of surgically maximized versus native membranous urethral length on 30-day and long-term pad-free continence after robot-assisted radical prostatectomy.
Impact of surgically maximized versus native membranous urethral length on 30-day and long-term pad-free continence after robot-assisted radical prostatectomy

Young Hwii Ko, Linda My Huynh, Kaelyn See, Chandana Lall, Douglas Skarecky, Thomas E. Ahlering

* Corresponding author. Department of Urology, University of California, Irvine 333 City Blvd West, Suite 2100, Orange, CA, 92868, USA.
E-mail address: tahlerin@uci.edu (T.E. Ahlering).

1. Introduction

Early recovery of urinary continence is a central goal of robot-assisted radical prostatectomy (RARP). Incontinence is recognized as the most important long-term outcome limiting the benefit of RARP, such that post-RARP incontinence was cited as a
major contributing factor to the 2012 United States Preventive Services Task Force recommendation that complications of prostate cancer treatment outweigh benefits of prostate-specific antigen (PSA) screening\(^1\). Even further, recovery of early continence is closely correlated with the patient quality of life\(^2\).

Membranous urethral length (MUL) has been explored both as a preoperative indicator of early continence recovery after RARP as well as the one which is amenable to surgical manipulation\(^3,4\). The first suggestion of a preoperative correlation was reported in 2002 by Coakley et al.\(^5\): men with longer multiparametric magnetic resonance imaging (mpMRI)--assessed MUL were ostensibly “pre-determined” to benefit from faster and more complete recovery of urinary continence after open RARP. Subsequently, in 2004, van Randenborgh et al.\(^6\) published the first findings of surgical maximization of MUL. Comparing 610 control RARP cases with 403 procedures performed with systematic preservation of the membranous urethra, they found that pad-free continence significantly improved from 76.02% to 88.4%\(^7\). These findings were revisited seven years later in 2011, by two different groups. First, Schloimm et al.\(^8\) demonstrated a significant improvement in 7-day pad-free continence after adoption of MUL maximization techniques during open RARP. The same technique was then applied to RARP by Hakimi et al.\(^9\), with similar success. Finally, Mungovan et al.\(^10\) published a systematic review that further focused on preexisting MUL. Increased the odds of pad-free continence by 9%. Although the results of the systematic review suggest stepwise benefit of longer innate MUL, we questioned if surgical maximization could trump this effect of predetermined MUL. In this study, we assessed the impact of surgically maximized MUL on early continence with cutting the dorsal venous complex (DVC) without prior stapling and stepwise release of the periurethral attachments, while concurrently evaluating for impact of innate mpMRI-assessed MUL.

2. Methods

2.1. Patients

A total of 605 men underwent RARP by a single surgeon: 370 cases underwent our standard, previously described procedure (stapling the DVC)\(^11\)-\(^15\), and 235 underwent RARP with surgical maximization of the membranous urethra. Of the 370 cases before technique change, 15 men were excluded because of lack of follow-up (Group 1, n = 355). Of the 235 cases subsequent to technique change, 10 men were similarly excluded because of lack of follow-up (Group 2, n = 225). Management protocol for both groups included perioperative Kegel exercises and post-RARP discharge with an indwelling urinary catheter that is removed 6-7 days after RARP.

Data including continent status, patient age, preoperative American Urological Association Symptom Score, PSA level, prostate weight, estimated blood loss, body mass index, pathologic stage, pathologic Gleason score, surgical margin status, and seminal vesicle invasion status were prospectively collected and entered into an electronic database under approval from an institutional review board protocol (HS# 1998-84). Complications were tracked via an institutional Data, Safety, and Monitoring Board and systematically recorded through postoperative Day 30.

2.2. Assessment of Preoperative MRI MUL

The impact of innate or preexisting preoperative MUL was assessed in men undergoing RARP with urethral length preservation. One hundred twenty-three patients underwent standard pelvic T3 MRIs (with and without contrast), and all studies were assessed by a single, specialized pelvic MRI radiologist. MUL was recorded from coronal and sagittal views of the pelvis, as the distance from the prostatic apex to the entry of the urethra into the penile bulb\(^16\). The radiologist was blinded to all clinical and urinary continence outcomes.

2.3. Surgical Technique and Anatomic Considerations

RARP in Group 1 was performed as previously described using an Ethicon Surgical Staplers J&J Medical Devices, Johnson and Johnson\(^17\). The anterior prostatic fat was removed, the endopelvic fascia was incised bilaterally, and the puboprostatic ligaments were transected to maximally release the apex so that the stapler could be easily applied for ligation and transection of the DVC (Video clip 1). The entire prostate was then freed in preparation for the last step: transection of the urethra and bagging the prostate.

In Group 2, to maximize preservation of MUL, the final step of removing the prostate was transection of the DVC and apical attachments (Video clip 2). The DVC is transected without ligation, allowing for full rotation of the prostate and circumferential tension—reduced release of the apical attachments: the external striated muscle and the membranous urethra. As experience dictated, a more definitive attempt was made to extend MUL as much as possible (Video clip 3). Reconstruction was the same throughout\(^17\), using a standard Rocco stitch\(^18\) followed by a van Velthoven anastomosis\(^19\). Per standard technique, no drains were placed in either group.

Supplementary video related to this article can be found at https://doi.org/10.1016/j.prnil.2019.12.005

2.4. Pad-free Continence Outcome Assessment

Since 2008, we have maintained a prospective, systematic, and highly redundant protocol to independently assess patient-reported “pad-free” continence status. We have extensively evaluated methods to accurately assess patient-reported time to pad-free continence after RARP. The methods have been externally audited and published and have shown to have reliable response rates of 74.3% to 85.1%\(^20\)-\(^24\). Via this system, pad-free continence was assessed in four ways. First, after catheter removal, all patients were asked to keep a daily log of the number of urinary pads used per 24 hours, to be electronically transmitted to our research team once the patient had achieved three consecutive days without use of pads. Second, patients were also given a pre stamped “pad-free” postcard that was also returned after three consecutive days of pad-free status. We previously showed excellent correlation between the pad-free cards and daily urinary pad logs in assessment of time-to-continence recovery\(^24\). Third, if we had no response after 30 days to either of the first two methods, patients were called by a nonclinical research associate for pad status. If the patient was not pad-free at 30 days, they were called again at 60 and 90 days, as needed. Fourth, pad status was assessed via patient-reported questionnaires at routine follow-up after RARP.

2.5. Learning Curve Analysis

As experience grew with the new technique, we queried the database for 30-day continence rates for evidence of a learning curve. Because of the need for just 30-day follow-up, we were able to expand this analysis up to 500 men. Thirty-day continence rates were also assessed in a similar manner in Group 1.
2.6. Statistical Analysis

Statistical analysis was conducted in SPSS, version 25, © International Business Machines Corporation (IBM) Corporation. The primary and secondary outcome measures were 30-day and 12-month pad-free continence, respectively. A tertiary outcome measure of time-to-continence recovery was also assessed. Two-sided student t tests were used to compare continuous variables. The Fisher exact and Pearson’s chi-square tests were used to compare categorical variables. Univariate associations between patient characteristics and continence recovery at 30 days and 12 months after RARP were examined using Pearson correlations. Multivariate associations between patient characteristics and continence recovery at 30 days and 12 months were analyzed using logistic regression models, adjusting for age, pathologic Gleason score, preoperative PSA, seminal vesicle involvement, pT2-positive margins, preoperative IIEF-5 International index of Erectile Function 5 (IIEF-5) score, and nerve-sparing status.

A p-value of < 0.05 was considered to be statistically significant, and variables that had significant univariate associations were included in the final multivariate models. Finally, time-to-continence recovery, as adjusted for significant covariates, was analyzed in cox regression modeling and plotted as a 1 - [S(t)] survival curve, stratified by technique change. Post hoc, a linear regression model was fitted to 30-day continence recovery curves to assess for learning curve effect after technique change. Goodness of fit was assessed with an R² coefficient of determination.

To assess the impact of innate MUL on continence, the aforementioned analysis was repeated for Group 2 patients with preoperative, mpMRI-assessed MUL. Receiver operator characteristic curves were generated with 30-day continence as the outcome measure, and a cutoff of 1.4 cm was determined to maximize sensitivity (93.2%) and specificity (88.1%). Using this cutoff, a power analysis was conducted based on level 0.05 (two-sided) test of equality of the probability for overall continence comparing patients with innate MUL > 1.4 cm with those with innate MUL ≤ 1.3 cm. A power analysis was performed based on our initial experience, where patients with an MUL > 1.4 cm recovered long-term pad-free continence 100% of the time, compared with 85% for patients with MUL ≤ 1.3 cm. Using this effect size, mpMRI-assessed MUL of 120 patients was required to achieve 90% power for detection of a 15% increase in the probability of continence.

3. Results

3.1. Demographics and Safety

Table 1 presents the demographics of both groups. By happenstance, the change in technique occurred approximately at the same time as the Grade D recommendation by the US Task Force against PSA screening in 2012. 25-26 Hence, preoperative age, PSA levels, clinical Gleason Grade (cGG), the number of cores involved, and % core involvement were higher among Group 2 men presenting for RARP, and pathologically, there was significantly more advanced disease (pGS, p-stage, and positive surgical margins, p < 0.05). Regarding safety of technique change, there were no significant increases in major or minor complications, estimated blood loss, 24-hour change in hemoglobin, or rate of pT2-positive surgical margins.

3.2. Urinary Continence Recovery

The accumulated patient-reported questionnaire response rates were 96.0% and 95.7% in Groups 1 and 2, respectively. In unadjusted analyses, the 30-day pad-free continence rates in Groups 1 and 2 were 28.2% (100/355) and 55.6% (125/225), respectively (p < 0.0001). The 1-year pad-free continence rates were 88.7% (315/355) and 93.8% (211/225), respectively (p = 0.0441). After adjusting for the aforementioned covariates, technique change improved both 30-day [odds ratio (OR): 3.671, 95% CI: 1.241-18.961] and 1-year continence recovery (OR: 1.886, 95% CI: 1.002-3.592) [Table 2]. Fig. 1 depicts adjusted Kaplan–Meier time-to-continence recovery curves between Group 1 and Group 2 (p < 0.0001). Both age and technique change were the only significant predictors of an earlier time-to-continence and 1-year continence recovery [Table 3].

3.3. Impact of MRI-assessed Preoperative MUL

A total of 123 (34.6%) from Group 2 had a preoperative, MRI-assessed MUL. The average MUL was 1.83 cm, with 16 (13%) having an MUL < 1.4 cm and 107 (87%) with MUL ≥ 1.4 cm, and clinical demographics were compared in Supplemental Table 1a. Thirty-day pad-free continence in these groups was 31.3% (5/16) and 59.8% (64/107), respectively (p = 0.033). Similarly, 1-year continence rates were 75% (12/16) and 96.2% (101/105), respectively (p = 0.0174).

In multivariate analysis, both categorical MUL > 1.4 cm (OR: 4.851, 95% CI: 1.241-18.961) and age (OR: 0.925, 95% CI: 0.873-0.980) were significant predictors of 30-day continence recovery (Supplemental Table 2a). MUL > 1.4 cm (OR: 11.255, 95% CI: 1.070-118.407) was the only significant predictor of 1-year continence recovery (Supplemental Table 2b).

3.4. Learning Curve Assessment

As our surgical experience progressed with the specific intent of increasing MUL, particularly posteriorly, we queried continence outcomes to assess for a learning curve. Fig. 2 illustrates a learning curve effect in Group 2 30-day continence rates (R² = 0.392) in our initial 500 patients, whereas no learning curve was identified in Group 1 30-day continence rates. In Fig. 3a, the line of transection of

| Table 1 Baseline characteristics of patients prior (Group 1) and subsequent (Group 2) to surgical technique change |
|---------|---------|---------|---------|
| Demographics | Group 1 (N = 355) | Group 2 (N = 225) | P |
| Mean | SD | Mean | SD |
| Age (years) | 61.6 | 7.5 | 62.8 | 7.4 | 0.054 |
| Preoperative IIEF-5 | 19.5 | 7.1 | 18.6 | 7.2 | 0.136 |
| PSA (ng/mL) | 6.7 | 6.8 | 10.2 | 17.9 | 0.007 |
| Prostate weight (g) | 53.4 | 20.9 | 54.2 | 21.2 | 0.676 |
| Estimated blood loss | 109 | 39.1 | 96.0 | 36.4 | <0.001 |
| Change in Hgb | 3.0 | 1.4 | 2.5 | 1.4 | <0.001 |
| AUASS | 8.6 | 6.9 | 8.0 | 6.7 | 0.292 |
| Body mass index | 26.7 | 3.5 | 26.7 | 3.6 | 0.968 |

SD, standard deviations; AUASS, American Urological Association symptom score; PSA, prostate-specific antigen; IIEF-5, International Index of Erectile Function - 5; SVI, Seminal Vesicle Invasion. Bold indicates p < 0.05.

We calculated as the difference between preoperative and 24-hour postoperative Hgb values.
the urethra few millimeters from the prostatic apex can be seen. As our experience progressed, we specifically addressed longer urethral length by releasing and transecting the urethra right at the prostatic apex (Fig. 3b). A statistically significant stepwise increase in 30-day continence rates from 50.8% to 67.7% was seen in the most recent 120 patients, \( p < 0.05 \).

### 4. Discussion

The first major publication regarding MUL by Coakley et al \(^{12}\) highlighted MRI-assessed MUL as an independent impactor of continence recovery after RARP. In their report, there was no mention that surgical preservation of MUL was a mechanism to increase continence recovery after RARP. It was not until 2004 and 2011 that van Randenborgh et al \(^{13}\) and Schlomm et al \(^{14}\) demonstrated convincing evidence that surgeons could physically preserve greater MUL during open RARP, to improve both time-to-continence and overall continence rates. An important question is whether surgical preservation can overcome an unfavorable innate MUL; alternatively, do both factors remain? In this regard, our study is the first to report that both findings, longer innate MUL and the surgical preservation of MUL, dramatically impact continence. Not only do our results further support that preservation of every millimeter of MUL is a critical factor surgeons can adapt but our analysis also supports that an innate component of MRI-assessed MUL \(^{15}\), independent of surgical preservation, impacts time-to-continence and overall urinary pad-free continence after RARP.

![One Minus Survival Function for patterns 1 - 2](image)

![Variables in the Equation](image)

**Table 2**

| Variables                      | B    | SE   | Wald  | \( p \)  | OR   | 95% CI         |
|--------------------------------|------|------|-------|----------|------|---------------|
| Technique change               | 1.3  | 0.191| 46.126| <0.001   | 3.671| 2.522 - 5.342 |
| Age (cont.)                    | 0.043| 0.014| 9.564 | 0.002    | 1.044| 1.016 - 1.073 |
| Preoperative PSA (<10 v. >10 [ref]) | -0.005| 0.008| 0.373 | 0.541| 0.995| 0.979 - 1.011 |
| pT2, positive margins          | -0.924| 0.544| 2.884 | 0.091| 0.397| 0.137 - 1.153 |
| Preoperative IIEF-5 (cont.)    | -0.025| 0.015| 2.652 | 0.103| 0.976| 0.947 - 1.005 |
| Nerve-sparing (any v. none [ref]) | -0.789| 0.582| 1.835 | 0.176| 0.454| 0.145 - 1.423 |
| Constant                       | -1.648| 1.168| 1.992 | 0.158| 0.192|               |

CI, confidence interval; OR, odds ratio; PSA, prostate-specific antigen; SE, standard error.
The primary finding of our study is that a technique change of surgical preservation followed by further attempts of maximization of MUL improved early continence—both 30-day and time to pad-free. The major strength of our study was the consistent nature and quality of patient-reported continence data collection before and after the change in technique. Critical to the reliability of the findings is data collection outside the outpatient/hospital setting. To this end, we reduced bias as our patients mailed or faxed their outcomes to us. This highly systematic, prospective, and redundant mechanism corroborated the two means of assessing patient-reported time to pad-free continence. Both daily urinary pad logs and/or pad-free continence postcards demonstrated excellent correlation in assessing patient-reported pad-free continence ($R^2 = 0.98$). By happenstance, changes in the United States prostate cancer screening practices in 2012 were coincident with our technique change and created significant demographic differences between Groups 1 and 2. However, even with older men and higher PSA levels in Group 2, the unadjusted 30-day continence rate

| Variables                                      | B     | SE    | Wald  | p     | OR     | 95% CI          |
|------------------------------------------------|-------|-------|-------|-------|--------|-----------------|
| Age (cont.)                                    | −0.063| 0.023 | 7.415 | 0.006 | 0.999  | 0.982 − 1.018   |
| Preoperative PSA (<10 v. >10 [ref])            | −0.232| 0.411 | 0.32  | 0.572 | 0.793  | 0.354 − 1.774   |
| pT2, positive margins                          | 0.438 | 0.79  | 0.307 | 0.580 | 1.549  | 0.329 − 7.288   |
| Preoperative IIEF-5 (cont.)                    | 0.014 | 0.635 | 1.745 | 0.187 | 0.432  | 0.973 − 1.057   |
| Nerve-sparing (any v. none [ref])              | −0.838| 0.635 | 0.004 | 0.951 | 2.73   | 0.125 − 10.6    |
| Constant                                       | 5.61  | 1.948 | 8.291 | 0.004 | 273.067|

CI, confidence interval; OR, odds ratio; PSA, prostate-specific antigen; SE, standard error.

Fig. 2. Learning curve of 30-day continence (per 50 patients) is shown.

Fig. 3. (A) Membranous urethral length (MUL) preparation early after technique change. Compared with (A) (below), there is transection of more striated sphincter, further from the prostatic apex (blue). (B) MUL preparation after learning curve, demonstrating stretching and rotating to maximally preserve MUL. Compared with (A) (above), the urethra is under greater traction, transected right on the prostate (blue), with less striated sphincter included.
increased from 28% (Group 1) to 56% (Group 2). After controlling for these factors in multivariate analysis, only age and technique change were significant predictors of continence. The effects of age were modest compared with MUL preservation: a patient in Group 2 was estimated to be 3.77 times more likely to recover pad-free continence at 30 days and 1.81 times more likely to recover by 1 year after RARP.

We observed and suggest that transecting the DVC without prior ligation (i.e., stapled, in our case) enhances tension-free, stepwise, and circumferential release of periurethral attachments. Before the completion of dividing the veins of the DVC, bleeding can impede visualization, complicating this approach. Fortunately, owing to the ambient pressure of the pneumoperitoneum (12 mmHg, which can be safely elevated to 18 mm for 5–10 minutes), once the veins are fully transected, minimal bleeding ensues until the prostate is removed. Although bleeding may initially be unnerving, it was never clinically relevant as no patient required transfusion. As noted in Table 1, the difference in preoperative and postoperative hemoglobin levels reduced from 3.0 to 2.5. Similar to Bianchi et al., we found no impact on our positive surgical margin rate. With experience, we also learned that the more the prostate was rotated, the easier it was to completely dissect the membranous urethra circumferentially, especially posteriorly. Comparing Fig. 2 with Fig. 3, greater MUL (in blue) was maximized as the urethra was transected closer and closer to the prostate. With experience and continued improvement noted in Fig. 2, there was a stepwise increase in 30-day continence rates, further inferring the importance of each millimeter of preservation and supporting the millimeter by millimeter benefit, as predicted by Mungovan et al. in 2017.

Limitations of the present study include a retrospective, single-surgeon study design. Assessment of technique change in a single surgeon reliably reduced variability in outcomes; it does not allow for the generalized applicability of a multicentered randomized control trial (RCT). However, RCTs are limited, as they are designed to control for a single confounder. By necessity, multicentered surgical RCTs are susceptible to at least two confounders: technique adoption and surgeon variability. Our personal experience with a multicentered high-volume-surgeon RCT revealed a significant impact of surgeon variability on powering.28–30. Given that we found a 30-fold difference in 30-day continence rates, the present study would require more than 120 patients per surgeon to attenuate the variability in surgical outcomes. The accompanying expenses and administrative oversight are typically prohibitive.

Previous studies primarily from Asia and Europe, combined with the present analysis, support the impact of innate MRI-assessed MUL and the importance of surgical maximization. However, given that this practice is more common among Asian centers, our findings suggest the need for increased emphasis of MUL maximization in Europe and the United States. Our findings also demonstrate that regardless of the benefit in maximizing MUL, an innate “predetermined” length of native membranous urethra less than approximately 1.4 cm reduces both 30-day and 1-year continence recovery. This innate MUL threshold appears to exist for about 15% of men.

5. Conclusion

Our findings add further support to both the innate impact of MRI-assessed MUL as well as the impact of each millimeter of MUL spared on early- and long-term pad-free continence. In our experience, the present technique of prostatic rotation and circumferential release of apical attachments effectively maximizes MUL during RARP.

Declaration of competing interest

The authors have no conflicts of interest.

Acknowledgments

This work was accomplished with special regards to Drs. Edward and Arthur Lui, in memory of their parents Mr. & Mrs. L.H.M. Lui. Special thanks to the research students, Whitney Zhang and Victoria Lee, for their dedication to data management and patient follow-up.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.prnil.2019.12.005.

References

1. Rodriguez E, Skarecky DW, Ahlering TE. Post-robotic prostatectomy urinary continence: characterization of perfect continence versus occasional dribbling in pad-free men. Urology 2006;67:785–9.
2. Ficarra V, Novaia G, Rosen R, Artibani W, Carroll PR, Costello A, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62:405–17.
3. Moyer V, on behalf of the U.S. Preventive Services task force. Screening for prostate cancer: u.s. preventive services task force recommendation statement. Ann Intern Med 2012;157:120–34.
4. Liss MA, Ossan K, Canvasser N, Chu W, Chang A, Gan J, et al. Continence definitions after radical prostatectomy using urinary quality of life: evaluation of patient reported validated questionnaires. J Urol 2010;183:1464–8.
5. Heesackers J, Farag F, Bauer R, Sandhu J, Ridder D, Stenzl A. Pathophysiology and contributing factors in postprostatectomy incontinence: a review. Eur Urol 2017;71:936–44.
6. Cho DS, Lee EJ, Kim SK, Kim S. The influence of membranous stretched urethral length and urethral circumference on postoperative recovery of continence after radical prostatectomy: a pilot study. Can Urol Assoc J 2015;9:5–6.
7. Satake Y, Kahi R, Saito H, Yamada T, Kawamorita N, Yamashita S, et al. Estimated minimal residual membranous urethral length on preoperative magnetic resonance imaging can be a new predictor for continence after radical prostatectomy. Urology 2018:138–44.
8. Song W, Kim CK, Park BK, Jeon HC, Jeong BC, Seo SI, et al. Impact of preoperative and postoperative membranous urethral length measured by 3 Tesla magnetic resonance imaging on urinary continence recovery after robotic-assisted radical prostatectomy. Can Urol Assoc J 2017;11:3–4.
9. Kadono Y, Nozuka T, Kawaguchi S, Naito R, Urata S, Nakashima K, et al. Investigating the mechanism underlying urinary continence recovery after radical prostatectomy: effectiveness of a longer urethral stump to prevent urinary incontinence. BJU Int 2018;122:456–62.
10. Paparel P, Akin O, Sandhu J, Otero JR, Seroi AM, Scardino PT, et al. Recovery of urinary continence after radical prostatectomy: association with urethral length and urethral fibrosis measured by preoperative and postoperative endorectal magnetic resonance imaging. Eur Urol 2009;55:629–39.
11. Walz J, Epstein J, Ganzer R, Graefen M, Guazzoni G, Kauko J, et al. A critical analysis of the current knowledge of surgical anatomy of the prostate related to optimisation of cancer control and preservation of continence and erection in candidates for radical prostatectomy: an update. Eur Urol 2016;70:301–11.
12. Lackley PV, Eberhardt S, Kattan MW, Wei DC, Scardino PT, Hricak H. Urinary continence after radical retropubic prostatectomy: relationship with membranous urethral length on preoperative endorectal magnetic resonance imaging. J Urol 2002;168:1032–5.
13. van Randenborgh H, Paul R, Kuhler H, Breul J, Hartung R. Improved urinary continence after radical retropubic prostatectomy with preparation of a long, partially intraprostatic portion of the membranous urethra: an analysis of 1013 consecutive cases. Prostate Cancer Prostatic Dis 2004;7:253–7.
14. Schlimm T, Heinzer H, Steuber T, Salomon G, Engel O, Michl U, et al. Full functional-length urethral sphincter preservation during radical prostatectomy. Eur Urol 2011;60:320–9.
15. Mungovan SF, Sandhu JS, Akin O, Smart NA, Graham PL, Patel ML. Preoperative membranous urethral length measurement and continence recovery following radical prostatectomy: a systematic review and meta-analysis. Eur Urol 2017; 368–78.
16. Huyub LM, Ahlering TE. Robot-assisted radical prostatectomy: a step-by-step guide. J Endourol 2018;32:528–32.
17. Ahlering TE, Eichel L, Edwards RA, Lee DJ, Skarecky DW. Robotic radical prostatectomy: a technique to reduce pT2 positive margins. Urology 2004;64: 1224–8.
18. Patel VR, Coelho RF, Paler KJ, Rocco B. Periurethral suspension stitch during robot-assisted radical prostatectomy: description of the technique and continence outcomes. Eur Urol 2009;56:472–8.

19. van Velthoven RF, Ahlering TE, Peltier A, Skarecky DW, Clayman RV. Technique for laparoscopic running urethrovesical anastomosis: the single knot method. Urology 2003;61:699–702.

20. Pick D, Skarecky DW, Osann K, Narula N, Finley D, Ahlering TE. The impact of cavernosal nerve preservation on continence following robotic radical prostatectomy. BJU Int 2011;108:1492–6.

21. Skarecky D, Morales B, Chang A, Ahlering T. Simple prediction method of return to pad-free continence for men undergoing robotic radical prostatectomy (RARP). J Endourol 2011;25:1451–5.

22. Ahlering T, Gordon A, Morales B, Skarecky D. Preserving continence during robotic prostatectomy. Curr Urol Rep 2013;14:52–8.

23. Gordon A, Skarecky DW, Ahlering T. Long-term outcomes in severe lower urinary tract symptoms in men undergoing robotic-assisted radical prostatectomy. Urology 2014;84:826–31.

24. Skarecky D, Van T, Morales B, Gordon A, Ahlering T. Continence postcards versus urinary pad logs: simple methods to measure early pad-free urinary continence after radical prostatectomy. Urol Pract 2014;4:378–82.

25. Barocas DA, Mallin K, Graves AJ, Penson DF, Palis B, Winchester DP, et al. Effect of the USPSTF grade d recommendation against screening for prostate cancer on incident prostate cancer diagnosis in the United States. J Urol 2015;194:1587–93.

26. Ahlering T, Huyhn LM, Kaler KS, William S, Osann K, Joseph J, et al. Unintended consequences of decreased PSA-based prostate cancer screening. World J Urol 2018. https://doi.org/10.1007/s00345-018-2407-3. Epub ahead of print.

27. Huyhn LM, Skarecky DS, Porter J, Wagner C, Witt J, Wilson T, et al. A randomized control trial of regional hypothermia on urinary continence during robot-assisted radical prostatectomy. Sci Rep 2018. https://doi.org/10.1038/s41598-018-34657-4.

28. Bianco FJ, Albala DM, Belkhoff LH, Miles BJ, Peabody JO, He W, et al. A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic-assisted radical prostatectomy. J Urol 2015. https://doi.org/10.1016/j.juro.2014.09.106.

30. Freiman JA, Chalmers TC, Smith H, Kubler RR. The importance of beta, the type ii error and sample size in the design and interpretation of the randomized control trial: survey of 71 negative trials. N Engl J Med 1978;299:690–4.

31. Hind D, Reeves BC, Barbers S, Bray C, Corkhill A, Hayward C, et al. Comparative costs and activity from a sample of UK clinical trials units. Trials 2017;18:203.

32. Frieden TR. Evidence for health decision making - beyond randomized controlled clinical trials. N Engl J Med 1978;299:690–4.

33. Hakimi AA, Faleck DM, Agalliu I, et al. Preoperative and intraoperative measurements of urethral length as predictors of continence after robot-assisted radical prostatectomy. J Endourol 2011;25:1025–30. https://doi.org/10.1089/end.2010.0692.